Scimago Lab
powered by Scopus
call: +1.631.629.4327
Mon-Fri 10 am - 2 pm EST


eISSN: 2329-0358

Home Page

Annals of Transplantation is one of the fast-developing journals open to all scientists and fields of transplant medicine and related research. The journal is published quarterly and provides extensive coverage of the most important advances in transplantation.
Using an electronic on-line submission and peer review tracking system, Annals of Transplantation is committed to rapid review and publication. The average time... read more

Published: 2019-01-15

Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Metastases in Solid Organ Graft Recipients: First Experience

Philipp Horvath, Can Yurttas, Florian Struller, Hans Bösmüller, Ulrich M. Lauer, Silvio Nadalin, Alfred Königsrainer, Marc André Reymond

(Department of General, Visceral and Transplant Surgery, University of Tübingen, Tübingen, Germany)

Ann Transplant 2019; 24:30-35

DOI: 10.12659/AOT.911905

BACKGROUND: Therapy of peritoneal metastases (PM) in solid organ transplant recipients is challenging. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) might constitute a new therapeutic opportunity for these patients.
MATERIAL AND METHODS: This was a single-center, retrospective analysis of prospective registry data (NCT03210298) in a tertiary care center between 1.7.2016 and 31.12.2017. Intraperitoneal administration of oxaliplatin 92 mg/m² body surface or a combination of cisplatin 7.5 mg/m² and doxorubicin 1.5 mg/m², repeated every 6 weeks. Objective tumor response was documented via histology (Peritoneal Regression Grading Score, PRGS), adverse events according to Common Terminology Criteria for Adverse Events (CTCAE) 4.0.
RESULTS: Out of 71 consecutive patients treated with PIPAC, 2 patients (2.8%) were solid organ transplant recipients. The first patient had metachronous PM of colonic cancer origin after liver transplantation. The second patient had synchronous PM of pancreatic cancer origin after combined kidney-pancreas transplantation. After repeated combined systemic and PIPAC chemotherapy, objective histological response was documented in both patients. No adverse events >CTCAE 2 were recorded. There was no measurable liver or renal toxicity. PIPAC procedures could be repeated (2, resp. 3 cycles) without any interruption of immunosuppressive medication or impairment of respective plasmatic drug levels. The first patient passed away 7 months after the first PIPAC, the second patient was still alive after 8 months.
CONCLUSIONS: PIPAC can induce objective regression of PM in solid organ transplant recipients without inducing organ toxicity or interfering with immunosuppressive therapy.

Keywords: Antineoplastic Agents, Organ Transplantation, Peritoneal Neoplasms

Related Articles (0)

Coming Soon...

Published: 2019-01-11

Kidney Transplantation in Children with Thrombosed Inferior Caval Vein – Atypical Vascular Anastomoses

Marek Szymczak, Piotr Kaliciński, Jacek Rubik, Dorota Broniszczak, Grzegorz Kowalewski, Marek Stefanowicz, Adam Kowalski, Mateusz Ciopiński, Ryszard Grenda

Ann Transplant 2019; 24:25-29

DOI: 10.12659/AOT.912657

Published: 2019-01-08

Pediatric Living-Donor Liver Transplant Recipients without Transition After Reaching Adulthood

Chikashi Nakanishi, Shigehito Miyagi, Kazuaki Tokodai, Wataru Nakanishi, Ryuichi Nishimura, Masafumi Goto, Michiaki Unno, Takashi Kamei

Ann Transplant 2019; 24:18-24

DOI: 10.12659/AOT.911544